Meridian Bioscience (VIVO) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Canaccord Genuity Cuts Price Target on Meridian Bioscience (VIVO) Following In-Line Quarter Results
July 27, 2015 9:18 AM EDTCanaccord Genuity reiterated a Hold rating on Meridian Biosciences (NASDAQ: VIVO), and cut the price target to $19.00 (from $20.00), following quarterly results. Revenues of $48.3M narrowly missed the Street's $48.6M. EPS of $0.22 was in line with the Street.
Analyst Mark Massaro... More
Meridian Bioscience (VIVO) Declares $0.20 Quarterly Dividend; 4.1% Yield
July 23, 2015 8:26 AM EDTMeridian Bioscience (Nasdaq: VIVO) declared a quarterly dividend of $0.20 per share, or $0.8 annualized.
The dividend will be payable on August 13, 2015, to stockholders of record on August 3, 2015, with an ex-dividend date of July 30, 2015.
The annual yield on the dividend is 4.1 percent.
For... More
